Programme Leader – Prof Simon Griffin
- Amy Ahern – Senior Investigator Scientist
- Clare Boothby – Data Scientist
- Hajira Dambha-Miller – NIHR Doctoral Research Fellow
- Christine Grainger – Programme Administrator
- Simon Griffin – Programme Leader
- Samantha Hajna – Research Associate
- Nazrul Islam – Quantitative Research Associate
- Emma Lawlor – Research Associate
- Jean Strelitz – MRC Postdoctoral Fellow
- Jenny Woolston – Study Coordinator
The overall goal of our research is to contribute to the prevention of the growing burden of obesity, type 2 diabetes and related metabolic disorders. We do this by translating epidemiological knowledge into action and evaluating the impact of different approaches to behaviour change and disease prevention. We are a multidisciplinary team of epidemiologists, clinicians, psychologists, and data scientists. Supported by a mix of MRC programme funding and external funding (for example NIHR and Wellcome Trust) we have established a programme of observational and experimental studies addressing key uncertainties that constrain policy decisions regarding the most appropriate and efficient distribution of scarce preventive resources.
The programme is characterised by meticulous phenotyping of participants (in particular precise measurement of behaviours), identification of modifiable determinants of behaviour and other risk factors for disease, prudent development of interventions informed by behavioural science theory, nesting of trials within well characterised cohorts, and extended follow-up to enable assessment of important clinical endpoints. Reducing the individual, economic and societal burdens of T2DM and related metabolic disorders necessitates a balance of individual and collective approaches. Examples may include anything from intensive medical treatment of patients at high risk, to screening for undiagnosed disease, to changes in transport or fiscal policy affecting the majority of the population. We collaborate with colleagues in CEDAR and the BHRU to develop and evaluate population-level approaches. In this programme we specifically focus on individual-level approaches to primary and secondary prevention.
Our aims are to:
- Quantify the impact of health behaviours on outcomes, and identify determinants of health behaviours
- Develop practical strategies to identify individuals or groups at increased risk of type 2 diabetes and related complications and likely to benefit from interventions
- Develop and evaluate ways to communicate information about health behaviours, risk factors and disease risk
- Develop and evaluate interventions to reduce the risk of diabetes and related metabolic disorders
Central to our research is a focus on translating knowledge into action. Our studies have provided the majority of original data referred to by international recommendations concerning screening for T2DM, including the HTA report for the UK National Screening Committee, and the US Preventive Services Task Force (USPSTF) review. We also contributed data to NICE and USPSTF guidance on weight management. Through membership of expert panels we have contributed to IDF and WHO evidence reviews concerning metabolic syndrome and prevention of T2DM. Our work on prevention of T2DM has influenced national policy via Nick Wareham serving as chair and Simon Griffin as an expert witness to NICE committees developing relevant public health guidance (PHG 35 and 38). Our work on screening for T2DM and CVD risk influences policy via membership of the NHS England Health Checks advisory board.
Dr Amy Ahern and Professor Simon Griffin co-lead the Scalable behavioural weight management programmes for the prevention and treatment of type 2 diabetes, which will examine the cost-effectiveness of using non-specialists (health trainers, community members) and technology (internet, phones) to deliver behavioural weight management programmes to people at high risk of developing type 2 diabetes and people with a recent diagnosis of type 2 diabetes.
- Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012;380:1741–48.
- Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GEHM, Sandbæk A, Sharp SJ, Simmons RK, van den Donk M, Wareham NJ, Lauritzen T. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011;378:156-167.
- Griffin SJ, Simmons RK, Prevost AT, Williams KM, Hardeman W, Sutton S, Brage S, Ekelund U, Parker RA, Wareham NJ, Kinmonth AL. Multiple behaviour change intervention and outcomes in recently diagnosed type 2 diabetes: the ADDITION-Plus randomised controlled trial. Diabetologia 2014;57:1308–1319.
Key studies and data sources used in our research include:
- Lena Alexander
- James Black
- Rishi Caleyachetty
- Parinya Chamnan
- Andrew Cooper
- Kirsten Corder
- Chris Craggs
- Justin Basile Echouffo-Tcheugui
- Adina Feldman
- Job Godino
- Laura Kuznetsov
- Maxine Lamb
- Michael Laxy
- Grainne Long
- Alison McMinn
- David Ogilvie
- Mushtaq Rahman
- Guy Shefer
- Barbora Silarova
- Rebecca Simmons
- Esther Van Sluijs
- Clare Watkinson
- Lin Yang